市場調査レポート

HPV (ヒトパピローマウイルス) 検査の世界市場

HPV Testing

発行 Global Industry Analysts, Inc. 商品コード 248886
出版日 ページ情報 英文 242 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
HPV (ヒトパピローマウイルス) 検査の世界市場 HPV Testing
出版日: 2015年04月01日 ページ情報: 英文 242 Pages
概要

当レポートでは、世界のHPV検査市場について調査し、2014〜2020年までの市場動向予測、製品概要、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • HPV検査市場:概要
    • 世界のHPV検査市場
    • 現在および将来分析
    • 子宮頸癌:発症率と死亡率の常勝が検査の必要性を高める
    • 一次スクリーニング適応のHPV検査が市場成長を牽引
    • 途上国が世界市場の成長を牽引
    • HPV検査の最新動向が明るい将来を約束
    • 償還対象がHPV検査の導入に影響を及ぼす
    • HPV予防接種プログラム:HPV検査市場への影響
    • 最も一般的かつ稀な副作用
    • Gardasil:バイオハザード
    • 吸入型子宮頸癌ワクチンが人気
    • HPVワクチンは男性の陰部疣贅の予防に効果が確証されている
    • 各国におけるHPV予防接種への取組み
  • 競合環境
  • 市場動向
  • 法規制環境
  • 細胞学とHPV検査概要
  • 製品導入/承認
  • 近年の業界活動
  • 主要企業
    • Abbott Molecular, Inc.
    • Arbor Vita Corporation
    • Becton, Dickinson and Company
    • DaAn Gene Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN N.V.
    • Seegene, Inc.
  • 世界市場見通し

第3章 国別市場

  • 米国
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
  • その他の諸国

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6893

This report analyzes the worldwide markets for HPV Testing in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as -

Abbott Molecular, Inc.
Arbor Vita Corporation
Becton, Dickinson and Company
DaAn Gene Co., Ltd.
F. Hoffmann-La Roche Ltd.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • HPV Testing Market - Quick Facts
  • Global HPV Testing Market: A Prelude
  • Current and Future Analysis
    • List of Select HPV Molecular Diagnostic Tests by Company and Technique
  • Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing
    • Major Risk Factors to HPV/Cervical Cancer
    • Table 1: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart)
    • Table 2: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart)
    • Table 3: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in '000s) (includes corresponding Graph/Chart)
  • HPV Testing for Primary Screening Indication Bodes Well for the Market's Growth
    • Table 4: Cervical Screening Penetration in Select Countries (2012): % of Women in 20-69 Age Group Screened for Cervical Screening(includes corresponding Graph/Chart)
  • Developing Markets to Drive Global Growth
    • Table 5: Number of HPV Tests by Geographic Region (2012) (In Million) (includes corresponding Graph/Chart)
    • Table 6: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)
    • Table 7: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)
    • Table 8: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 9: Global HPV Testing Market by Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)
  • Latest Developments in HPV Testing Promise Bright Future Ahead
  • Reimbursement Coverage Influences Adoption of HPV Testing
  • HPV Vaccination Programs: Assessing the Impact on HPV Testing Market
  • Some of the most common and rare side effects include:
  • Gardasil - A Biohazard?
    • Side-effects of Gardasil More Apparent among Preteens
  • Inhalable Cervical Cancer Vaccines to Grow in Popularity
  • HPV Vaccine Proves Beneficial in Prevention of Genital Warts in Men
  • HPV Vaccination Initiatives in Select Countries
    • HPV Vaccine Implementation: HPV Immunization Schedule and Population Coverage by Country

2. COMPETITIVE LANDSCAPE

  • Qiagen, the Global Leader Face Headwinds from Roche
    • Table 10: Assessing the Impact of FDA's Approval of Roche's HPV Test on HPV Sales of Market Majors: Y-O-Y Quarterly HPV Sales Growth for QIAGEN, Hologic and Roche
    • Table 11: Leading Players in the Global HPV Testing Market (2014E): Percentage Share Breakdown of Revenues for Abbott, Becton Dickinson, Hologic/Gen-probe, QIAGEN, Roche, and Others (includes corresponding Graph/Chart)
  • Comparative Analysis of HPV Testing Products
  • A Review of Select HPV Tests
  • digene HC2 HPV DNA Test
  • digene HC2 High-Risk HPV DNA Test
  • careHPV Test
  • Cervista HPV HR Test
  • Cervista HPV 16/18 Test
  • Cobas 4800 HPV test
  • Aptima HPV Assay

3. MARKET DYNAMICS

  • HPV Testing: A Fast Growing Segment in the STD Diagnostic Testing Market
  • Pap Cytology and HPV Co-testing: Improved Determination of Cervical Cancer Risk
  • Cervical Cytology Screening: An Abstract
    • Conventional Pap Smear Tests Give Way to Liquid-based Cytology Tests
    • Table 12: Pap Tests Market in Select Countries (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart)
    • Table 13: Pap Smear Tests by Geography (2014E): Percentage Breakdown by Number of Tests for US, EU and Asia & Latin America (includes corresponding Graph/Chart)
  • Non-Invasive Urine HPV Test Holds Potential to Replace Pap Smear Test
  • Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
  • Regular HPV Screening Enhances Treatment and Survival Options
  • Need for Genotyping of HPV Subtypes Beyond 16 & 18
  • Detecting E6 and E7 Oncoproteins to Improve Efficacy of Cervical Cancer Screening
  • Novel Technological Developments to Enhance Accuracy of Screening Procedures
  • Use of Non-FDA Approved Tests for HPV Testing: A Major Concern
  • Increase in Instances of HPV-Linked Oral Cancer - A Cause of Deep Concern
  • Research Findings Indicate Two Vaccination Doses Equal Three
  • Men Found to be More Susceptible to Oral HPV Infections

4. REGULATORY LANDSCAPE

  • Favorable Guidelines: A Key Growth Driving Factor
  • Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015
      • Capitulation of Cervical Cancer Screening Guidelines (2009-2012)
  • Revised Guidelines for Cervical Cancer Screening: 2012
  • HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the US
  • US Government Proposes Administration of HPV Vaccine for Males

5. OVERVIEW OF CYTOLOGY AND HPV TESTING

  • What is HPV?
  • Types of HPV
  • Commonly Known Diseases and Related HPV Test Types
  • Common Types of HPV Diseases
  • Lung Cancer
  • Cutaneous HPVs
  • Genital HPVs
  • Throat Cancer
  • Causes of Infection
  • Cervical Cancer and HPV
  • HPV and Other Cancers
  • Techniques for Detecting HPV
  • Signal-Amplified Nucleic Acid Assays
  • Target-Amplified HPV Assays
  • What is HPV Testing?
  • Test of HPV in Men
  • Test of HPV in Women
  • HPV Test Results
  • Limitations of HPV Testing
  • Advantages of HPV Testing
  • Cervical Cytology Observation/Screening
  • Pap Smear Screening
  • Requirements for Pap Smear Test
  • Advantages of Pap smear Test
  • Limitations of Cytologic Screening
  • HPV Testing vs. Cytology Testing

6. PRODUCT INTRODUCTIONS/APPROVALS

  • Abbott Introduces RealTime High Risk HPV Test
  • Advanced Cell Diagnostics to Introduce HPV Assay Based on RNAscope Technology
  • Roche Receives US FDA Approval for cobas HPV Test for First-Line Primary Screening for Cervical Cancer in Women
  • Cepheid Releases Xpert® HPV Test for Cervical Cancer-Related HPV
  • Qiagen Introduces careHPV™ Test in India
  • BD Diagnostics Gains CE/IVD Marking for BD Onclarity™ HPV Assay
  • Hologic Gains FDA Approval for Aptima HPV 16 18/45 Genotype Assay
  • QIAGEN Launches careHPV Test in China
  • Roche Seeks Initial Screening Indication for Cobas HPV Test
  • Hologic Secures Approval for Aptima HPV Assay from US FDA
  • Cancer Genetics Introduces FHACT™ Test
  • CureHealth Diagnostics Unveils New HPV Detection Technology in India
  • Abbott Rolls Out RealTime High Risk HPV Test in Canada
  • Trovagene Launches HPV-HR Test
  • Hologic Bags FDA Approval for Using APTIMA HPV 16 18/45 Genotype Assay with TIGRIS System
  • FDA Grants Approval for Gen-Probe's PANTHER® System
  • GenPath Women's Health Rolls Out GenCerv HPV Test
  • Seegene Unveils QuantPlex HPV28 Genotyping Assay
  • QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System in Europe

7. RECENT INDUSTRY ACTIVITY

  • Cancer Genetics Acquires BioServe India
  • Arbor Vita Enters into Distribution Agreement with AB ANALITICA
  • Australian MSAC Recommends HPV Testing as Primary Cervical Cancer Screening Tool
  • CytoCore Announces Name Change to MEDITE Cancer Diagnostics
  • Enzo Ties up with IncellDx Inc
  • IncellDx Inks Agreement with GeneCell Diagnostics
  • IncellDx and Kindstar Global Ink Agreement
  • Quest Diagnostics and Hologic Enter into Strategic Alliance
  • QIAGEN and Calmette Hospital Enter into Partnership
  • Hologic Acquires Gen-Probe
  • QIAGEN Enters into Co-Marketing Agreement with KingMed Diagnostics
  • Gynecor Implements cobas® 4800 Analyzer for HPV Test
  • Molecular Pathology Laboratory Network to Adopt Hologic/Gen-Probe APTIMA HPV Assay
  • Trovagene Inks Agreement with Strand Life Sciences
  • Bio-Reference Laboratories Acquires Stake in InCellDx
  • QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics
  • Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV Testing in UK

8. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Molecular, Inc. (US)
  • Arbor Vita Corporation (US)
  • Becton, Dickinson and Company (US)
  • DaAn Gene Co., Ltd. (China)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hologic, Inc. (US)
  • QIAGEN N.V. (The Netherlands)
  • Seegene, Inc. (South Korea)

9. GLOBAL MARKET PERSPECTIVE

    • Table 14: World Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/ Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review for HPV Testing by Geographic Region/Country - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 16: World 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Cervical Cancer in the US - Key Statistics & Findings
    • Table 17: Key Facts on Cervical Cancer in the US: 2014
    • Table 18: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)
    • Table 19: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart)
    • Table 20: Number of New Cervical Cancer Cases by US State (2015)
    • Table 21: Incidence and Mortality Rate of Cervical Cancer by Ethnicity in the US (2007-2011) (includes corresponding Graph/Chart)
    • HPV Testing Market - A Review
    • Table 22: Cervical Cancer by HPV Type (2014E): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart)
      • Use of Non-FDA Approved Tests for HPV Testing: A Major Concern
      • Competitive Landscape
    • Table 23: Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart)
    • Cytology Testing Market - An Insight
    • Table 24: Pap Tests Market in the US (2014E): Percentage Share Breakdown of Number of Tests by Conventional Cytology Tests and Liquid-based Cytology Tests (includes corresponding Graph/Chart)
    • HPV Vaccine Implementation
    • Reimbursement of Screening Procedures
    • Regulatory Landscape
      • Recommendations of Interim Guidance Report Issued by SGO and ASCCP: Jan 2015
      • Overview of Cervical Cancer Screening Guidelines
      • Revised Guidelines for Cervical Cancer Screening: 2012
      • 2011: US Government Proposes Administration of HPV Vaccine for Males
      • HPV Vaccine Implementation in the US Sates
      • HPV Vaccines Legislations Passed by Individual US States (2011-2012)
    • Product Introductions/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 25: US Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 26: US Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Outlook
    • Key Statistics in a Nutshell
    • Table 27: Cervical Cancer in Japan (2014E): Percentage Share Breakdown of New Cases and Number of Deaths by Age Group (includes corresponding Graph/Chart)
    • Table 28: Crude HPV Prevalence (%) in Women with Normal Cytology by Age Group (2014) (includes corresponding Graph/Chart)
    • Table 29: Japanese HPV Market (2012): Leading HPV Types Causing Cervical Cancer (includes corresponding Graph/Chart)
    • Japan Discontinues Recommendation of FDA Approved HPV Drugs
  • B. Market Analytics
    • Table 30: Japanese Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 31: Japanese Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Outlook
    • Cervical Cancer Screening in Europe - A Review
    • Table 32: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart)
    • Table 33: Estimated New Cervical Cancer Cases per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 34: Number of Deaths due to Cervical Cancer per Year in Europe by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 35: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)
    • Table 36: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 37: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 38: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)
    • Table 39: Cervical Cancer Incidence and Mortality in European Countries (2012) (includes corresponding Graph/Chart)
    • Table 40: Prevalence of Cervical Cancer in European Countries (2012) (includes corresponding Graph/Chart)
      • Increasing Effectiveness of Cervical Cancer Screening Programs
      • Need for Repeat Testing
    • HPV - The Preferred Primary Screening for Cervical Cancer in Europe
    • Product Introductions/Approvals
  • B. Market Analytics
    • Table 41: European Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 42: European Historic Review for HPV Testing by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)
    • Table 43: European 12-Year Perspective for HPV Testing by Geographic Region/Country - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2015 and 2020 (includes corresponding Graph/Chart)

3a. FRANCE

  • A. Market Analysis
    • Outlook
    • Cervical Cancer in France - A Review
    • Table 44: Key Facts on Cervical Cancer in France: 2014
    • Table 45: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • HPV Vaccine Implementation
  • B. Market Analytics
    • Table 46: French Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 47: French Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3b. GERMANY

  • A. Market Analysis
    • Outlook
    • Cervical Cancer in Germany - A Review
    • Table 48: Key Facts on Cervical Cancer in Germany: 2014
    • Table 49: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 50: German Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 51: German Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3c. ITALY

  • A. Market Analysis
    • Outlook
    • Cervical Cancer in Italy - A Review
    • Table 52: Key Facts on Cervical Cancer in Italy: 2014
    • Table 53: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 54: Italian Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 55: Italian Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Market Overview
    • Cervical Cancer - Key Statistics
    • Table 56: Key Facts on Cervical Cancer in the UK: 2014
    • Table 57: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • Impact of HPV Vaccine Implementation
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 58: UK Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 59: UK Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

3e. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Spain
    • Table 60: Cervical Cancer in Spain (2012): Percentage Share Breakdown of New Cases by Age-Group (includes corresponding Graph/Chart)
    • Table 61: Key Facts on Cervical Cancer in Spain: 2014
    • Table 62: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • Sweden
    • Table 63: Key Facts on Cervical Cancer in Sweden: 2014
    • Table 64: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • The Netherlands
    • Table 65: Key Facts on Cervical Cancer in the Netherlands: 2014
    • Table 66: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • Russia
    • Table 67: Key Facts on Cervical Cancer in Russia: 2014
    • Table 68: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 69: Rest of Europe Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 70: Rest of Europe Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Focus on Select Markets
      • Canada
      • The Canadian Task Force on Preventive Health Care (CTFPHC) Recommendations for Cervical Cancer Screening: 2013
    • Table 71: Key Facts on Cervical Cancer in Canada: 2014
    • Table 72: Estimated Age-Standardized Incidence Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart)
    • Table 73: Estimated Age-Standardized Mortality Rates of Cervical Cancer per 100,000 Women Population in Canada by Province (2014) (includes corresponding Graph/Chart)
    • Table 74: Prevalence of HPV16 and HPV18 among Women in Canada by Cytology (2014) (includes corresponding Graph/Chart)
      • Asia-Pacific
    • Table 75: Key Facts on Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart)
    • Table 76: Incidence of Cervical Cancer in Asia by Region: 2012 (includes corresponding Graph/Chart)
    • Table 77: Estimated New Cervical Cancer Cases per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 78: Number of Deaths due to Cervical Cancer per Year in Asia by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 79: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart)
    • Table 80: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 81: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 82: HPV Testing Market in Asia by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart)
      • China
      • Introduction
    • Table 83: Key Facts on Cervical Cancer in China: 2014
    • Table 84: Prevalence of HPV16 and HPV18 in China by Cytology (2014) (includes corresponding Graph/Chart)
      • New Testing Technologies Gain Traction
      • Competitive Landscape
    • Table 85: Leading Players in China's HPV Market (2012): Percentage Share Breakdown of Value for Digene, Kaipu, Yaneng, Mingyuan and Others (includes corresponding Graph/Chart)
      • India
      • HPV Testing - A Nascent Market
      • TABLE 86: HPV Prevalence by Histology (includes corresponding Graph/Chart)
    • Table 87: Prevalence of HPV Types 16 and 18 among Women in India - Breakdown by Cytology (includes corresponding Graph/Chart)
    • Table 88: Top 10 HPV Oncogenic Types among Women in India (2012): Breakdown of Prevalence (%) by Cytology
    • Table 89: Most Common HPV Oncogenic Types among Women with Invasive Cancer in India (2012): Breakdown of Prevalence (%) by Histology
      • Cervical Cancer Screening in India - Still a Long Way to Go
    • Table 90: Key Facts on Cervical Cancer in India: 2012
    • Table 91: Cervical Cancer Incidence and Mortality in India: 2012
    • Table 92: Estimated New Cervical Cancer Cases Per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart)
    • Table 93: Number of Deaths due to Cervical Cancer per Year by Age Group in India (As of 2012) (includes corresponding Graph/Chart)
    • Table 94: Crude Incidence Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart)
    • Table 95: Crude Mortality Rate of Most Common Cancers among Women of all Ages in India: 2012 (includes corresponding Graph/Chart)
      • Australia
    • Table 96: Key Facts on Cervical Cancer in Australia: 2014
    • Table 97: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
      • National Cervical Screening Program Continues to Taste Success
      • Cervarix® and Gardasil® to Combat Cervical Cancer
      • New Zealand
    • Table 98: Key Facts on Cervical Cancer in New Zealand: 2014
    • Table 99: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology
      • Latin America
    • Table 100: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)
    • Table 101: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 102: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 103: Latin America HPV Testing Market by Select Region (2014): Breakdown by Number of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)
      • Brazil
    • Table 104: Key Facts on Cervical Cancer in Brazil: 2014
    • Table 105: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
      • Mexico
    • Table 106: Key Facts on Cervical Cancer in Mexico: 2014
    • Table 107: Prevalence of HPV Types of 16 and/or 18 among Women by Cytology (includes corresponding Graph/Chart)
      • Africa
    • Table 108: Key Facts on Cervical Cancer in Africa: 2014
    • Table 109: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Normal Cytology (includes corresponding Graph/Chart)
    • Table 110: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Low-Grade Lesions (includes corresponding Graph/Chart)
    • Table 111: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with High-Grade Lesions (includes corresponding Graph/Chart)
    • Table 112: HPV Testing Market in Africa by Region (2014): Breakdown by No. of Women Tested and Prevalence of HPV 16/18 in Women with Cervical Cancer (includes corresponding Graph/Chart)
    • Table 113: Cervical Cancer Incidence in Africa by Region: 2012 (includes corresponding Graph/Chart)
    • Table 114: Estimated New Cervical Cancer Cases per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 115: Number of Deaths due to Cervical Cancer per Year in Africa by Region and Age Group: 2012 (includes corresponding Graph/Chart)
    • Table 116: Age-Standardized Cervical Cancer Incidence Rates in Africa by Region: 2012 (includes corresponding Graph/Chart)
    • Table 117: Age-Standardized Cervical Cancer Mortality Rates in Africa by Region: 2012 (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 118: Rest of World Recent Past, Current and Future Analysis for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2014 through 2020 (includes corresponding Graph/Chart)
    • Table 119: Rest of World Historic Review for HPV Testing Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2013 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top